Imugene CEO Leslie Chong Highlights Promising Blood Cancer Data

Why It Matters

The data suggests Imugene may fill a therapeutic gap for patients ineligible for existing CAR‑T treatments, potentially driving partnerships and boosting its valuation.

Key Takeaways

• Cohort two targets CAR‑T naive blood‑cancer patients across multiple subtypes.
• Basket study shows responses in CLL, marginal zone, Waldenström, follicular lymphoma.
• CLL and marginal‑zone patients maintain responses up to six‑seven months.
• One CLL case progressed from partial to complete response after five months.
• Investors and pharma executives expressed strong interest and asked many questions.

Summary

Imugene CEO Leslie Chong unveiled results from Cohort 2, a basket trial targeting blood‑cancer patients who have never received an autologous CAR‑T therapy. The study spans chronic lymphocytic leukemia, marginal‑zone lymphoma, Waldenström macroglobulinemia and follicular lymphoma, and early data indicate objective responses across these indications.

Responses in CLL and marginal‑zone patients have persisted for six to seven months, and one CLL participant transitioned from a partial to a complete response after roughly five months, achieving full tumor marker clearance. The durability and depth of these remissions are notable given the difficulty of attaining complete responses in these diseases.

Chong highlighted the “complete clearance and markers of tumors” as a key signal, noting that physicians, investors and pharmaceutical representatives in the audience asked extensive questions, reflecting strong market interest.

If validated, the data could position Imugene’s platform as a viable option for CAR‑T‑naïve patients, opening pathways for further clinical development, strategic partnerships and potential market entry.

Original Description

Imugene CEO Leslie Chong discusses the company's standout ASCO presentation, where new Azer-Cel data attracted strong interest from oncologists, investors and pharmaceutical companies. The latest results showed durable responses in blood cancer patients, including a CLL patient who achieved a complete response. Imugene is now advancing both its CAR-T naïve study and a BTK inhibitor combination program, creating multiple clinical catalysts ahead.